Connecticut Follows within the Footsteps of Different Jurisdictions Requiring Registration of Pharmaceutical Representatives


Connecticut is the newest state to hitch the efforts of jurisdictions comparable to Oregon, Nevada, Washington D.C., and the Metropolis of Chicago, Illinois, in additional regulating the actions of pharmaceutical representatives. In June, Governor Ned Lamont signed into regulation “An Act Defending Sufferers and Prohibiting Pointless Well being Care Prices” (the “Act”), which imposes new registration, reporting, and disclosure necessities on pharmaceutical representatives within the State of Connecticut. The Act builds on Governor Lamont’s coverage initiatives, which intention to enhance the supply of care and cut back healthcare prices for Connecticut residents and contains the initiative to manage pharmaceutical advertising and marketing practices. The Act units forth sure necessities for pharmaceutical producers and “pharmaceutical consultant(s)” which stay topic to additional clarification primarily based on any forthcoming steerage and rules from the Connecticut Division of Shopper Safety (“CT DCP”).

The Act went into impact on October 1, 2023 and requires pharmaceutical producers that make use of any particular person to carry out duties of a so-called “pharmaceutical consultant”[i] in Connecticut to: (a) register yearly with the CT DCP as a “pharmaceutical advertising and marketing agency;” (b) report back to the CT DCP numerous data on all people employed by the pharmaceutical advertising and marketing agency as a pharmaceutical consultant; and (c) disclose every pharmaceutical consultant’s exercise up to now calendar yr in an annual report back to the CT DCP.[ii] Along with these necessities, pharmaceutical representatives engaged in legend drug advertising and marketing in Connecticut should disclose in writing, on the time of every contact, the next data to prescribing practitioners or pharmacists: (i) the listing value of a legend drug, primarily based on the dose and amount of such legend drug as described within the treatment package deal insert; and (ii) data on the variation efficacy of the legend drug marketed to totally different racial and ethnic teams, if such data is obtainable.[iii] The Act additionally authorizes the CT DCP to impose penalties for situations of non-compliance or violations of the Act.


Not like related necessities in different jurisdictions, the Act primarily focuses on drug producers and prescribed drugs, however is mostly relevant to “pharmaceutical producers”, together with digital pharmaceutical producers, that make use of “pharmaceutical representatives” the place:

Pharmaceutical producer” is outlined to incorporate (a) “an individual, whether or not inside or with out the boundaries of the state of Connecticut, that prepares, cultivates, grows, propagates, compounds, converts or processes a drug, system or beauty, immediately or not directly, by extraction from substances of pure origin, by chemical synthesis or by a mixture of extraction and chemical synthesis, or that packages, repackages, labels or relabels a container beneath such producer’s personal trademark or label or another trademark or label, or a drug, system or beauty for the aim of promoting the drug, system or beauty;” or (b) “a sterile compounding pharmacy, as outlined in part 20-633b of the final statutes that dispenses sterile prescription drugs with no prescription or a patient-specific medical order meant to be used in people.”

“Pharmaceutical consultant” is outlined broadly to incorporate “any individual, together with, however not restricted to, a gross sales consultant, who markets, promotes or gives data relating to a legend drug for human use to a prescribing practitioner and is employed or compensated by a pharmaceutical producer.” [iv]

Of be aware is that in earlier variations of the invoice “medical science liaisons” have been included inside the definition of pharmaceutical consultant; nevertheless, this language was eliminated within the closing model of the Act.[v] Although the definition of “pharmaceutical consultant” contains these individuals who “[provide] data” to prescribing practitioners, primarily based on the exclusion of medical science liaison from the definition of pharmaceutical consultant, pharmaceutical producers could also be inclined to limit the definition of “pharmaceutical consultant” to individuals who act and supply such data in a promotional or advertising and marketing capability except additional steerage or rules point out in any other case. It stays to be seen whether or not subsequent rules will additional make clear the applicability of this regulation to sure particular person roles that will not neatly fall inside the Act’s definitions. Within the meantime, pharmaceutical producers using people who promote, market, or present data on legend medicine to prescribing practitioners and pharmacists in Connecticut might contemplate evaluating worker roles and job descriptions to establish whether or not sure employed people might have to be included or excluded from any reporting and disclosure necessities beneath the Act.

What Do Pharmaceutical Producers Have to Do?

Register. As of October 1, 2023, a pharmaceutical producer that employs people as pharmaceutical representatives should register as a pharmaceutical advertising and marketing agency with the CT DCP and renew their registration yearly, and by no later than June 30th of every yr. Failure to well timed renew a registration will lead to a late price of $100 for every year that the pharmaceutical advertising and marketing agency didn’t correctly renew, along with the annual renewal price. Moreover, every pharmaceutical advertising and marketing agency should: (a) present the CT DCP with an inventory of all people employed by the agency as a pharmaceutical gross sales consultant with its preliminary registration and every annual renewal and (b) notify the CT DCP of any people who’re employed by the agency or not employed by the agency inside two weeks of the change.

Report. To ensure that any particular person to carry themselves out as a pharmaceutical consultant to prescribers or pharmacists in Connecticut, that particular person’s employer should be registered as a pharmaceutical advertising and marketing agency, and any one that shouldn’t be on a pharmaceutical advertising and marketing agency’s registration listing, which shall be posted publicly on the CT DCP’s web site, might not act as a pharmaceutical consultant on behalf of such agency. Given the Act’s broad definitions, this may increasingly imply that in Connecticut, workers who historically might not be thought-about “pharmaceutical representatives” should be included within the listing of pharmaceutical representatives disclosed to the CT DCP if their duties contain the advertising and marketing, promotion or provision of knowledge relating to a legend drug for human use to a prescribing practitioner or pharmacist.

Disclose. Additional, beginning July 1, 2024, every pharmaceutical advertising and marketing agency should present the next data from the prior calendar yr for every of its pharmaceutical representatives, the place “contact” is outlined as any communication transmitted in individual or by phone, email correspondence, textual content message or different digital means to advertise or present data associated to a legend drug: (a) the combination variety of contacts every pharmaceutical consultant had with prescribing practitioners and pharmacists; (b) the specialty of every prescribing practitioner or pharmacist with which a pharmaceutical consultant had contact; (c) whether or not the pharmaceutical consultant offered any product samples, supplies, or items of worth to any pharmacist or to any prescribing practitioner or their workplace workers members; and (d) an combination report of all free samples offered by the pharmaceutical consultant, organized by drug identify and energy.[vi] As with the listing of pharmaceutical representatives offered by registered pharmaceutical advertising and marketing companies, the CT DCP will compile and put up a report of all disclosures made pursuant to this annual requirement.


Pharmaceutical producers ought to guarantee they’re in compliance with the Act’s necessities because the CT DCP is permitted by the Act to (a) refuse to situation or renew a agency’s registration, (b) revoke, droop, or impose situations on a agency’s registration, and (c) impose penalties of as much as $1,000 per violation.

Different Jurisdictions of Notice

Along with Connecticut, every of the jurisdictions under have an analogous requirement for people advertising and marketing or selling prescription drugs to healthcare professionals (“HCP”).

Oregon. Efficient January 1, 2022, a person in Oregon who acts as a pharmaceutical consultant for greater than 15 days in the course of the calendar yr should have, and renew yearly, a license from the Division of Shopper and Enterprise Companies (“DCBS”). An applicant may even have to fulfill sure prelicensure necessities and full persevering with training to keep up their license. Moreover, pharmaceutical representatives should keep their very own disclosure log documenting their interactions with well being care suppliers, which can also be revealed on the DCBS web site.[vii] Violations could be topic to a penalty of $1,000 to $3,000 per violation, the place every day that a person is in violation of this regulation constitutes a separate violation.[viii]

Chicago, Illinois. Efficient July 1, 2017, the Chicago Municipal Code requires that a person who markets or promotes prescription drugs to HCPs inside the Metropolis of Chicago for greater than 15 calendar days in the course of the yr should have a license from the Metropolis of Chicago’s Division of Enterprise Affairs and Shopper Safety. Sure exemptions embrace medical science liaisons, wholesale distributors, and pharmaceutical consultant managers or supervisors who don’t work together immediately with HCPs whereas within the Metropolis of Chicago. As with Oregon’s necessities, licensees in Chicago should additionally full an academic course for each the preliminary license in addition to any subsequent renewals, that are topic to audit by the Chicago Division of Public Well being. Violations of the tutorial necessities could be topic to fines $1,000 to $3000 per day of violation.[ix]

Nevada. Efficient October 1, 2017, a person who resides in or visits Nevada for 5 or extra days per yr to interact within the advertising and marketing of prescribed drugs, to interact HCPs relating to a drug product, or to distribute FDA regulated product samples and data should be registered as a pharmaceutical consultant with the Nevada Division of Well being and Human Companies by October 1st of the yr or inside 30 days of rent, and in both case, should be registered earlier than initiating any actions as a pharmaceutical consultant. Exclusions embrace people attending any conferences or conventions in Nevada not solely marketed to Nevada licensed HCPs, actions associated to scientific trial or investigational medicine, and actions carried out by distributors who don’t signify a single producer.[x] As with the Act, an using producer in Nevada can submit the names of all pharmaceutical representatives in a single registration report and should replace the Division of Well being and Human Companies of any adjustments to their workers who could also be beginning any actions as a pharmaceutical consultant or who’s terminated. [xi]

Washington D.C. Efficient October 1, 2008, a person who operates as a pharmaceutical detailer who sells, gives data on, or promotes a pharmaceutical product in any method should be licensed with the District of Columbia Board of Pharmacy. Licensing necessities embrace proof of commencement from the next training establishment along with licensure charges and a notarized assertion that the candidate will abide by sure necessities, together with a code of ethics. As with different jurisdictions, an applicant should additionally full persevering with training and should, topic to the Board of Pharmacy’s request, be required to supply data relating to communications with HCPs within the District of Columbia.[xii]

What’s Subsequent?

As evidenced by the Act and the prevailing legal guidelines in Oregon, Nevada, Washington D.C., and the Metropolis of Chicago, there’s a rising development in jurisdictions searching for to manage pharmaceutical representatives who interact with prescribing practitioners and pharmacists. Some jurisdictions transcend registration, reporting, and disclosure necessities and impose stricter licensing and training necessities. Pharmaceutical producers and people partaking within the advertising and marketing, promotion, or dialogue of drug merchandise with HCPs ought to be certain that they’re abiding by the registration or licensing necessities of the jurisdictions wherein they function, and may hold a watch out for laws in different jurisdictions as it’s potential that different jurisdictions will begin exploring related necessities. Additional, as necessities for licensure, registration, renewal, persevering with training and disclosures differ, you will need to fastidiously assess and ensure that every one pharmaceutical producers and particular person pharmaceutical representatives are in compliance with every jurisdiction’s necessities.

As Connecticut begins to implement the Act, pharmaceutical producers ought to proceed to maintain an in depth eye on any implementing rules and monitor the CT DCP’s Web site on Pharmaceutical Advertising and marketing Agency Registration for any updates to the registration, reporting, and disclosure necessities.


[i] See Connecticut Public Act No. 23-171 Sec. 3. (2023).

[ii] See Connecticut Public Act No. 23-171 Sec. 4. (2023).

[iii] See Connecticut Public Act No. 23-171 Sec. 5. (1)(2) (2023).

[iv] Connecticut Public Act No. 23-171 Sec. 3. (8) (2023).

[v] Evaluate OLR Invoice Evaluation sHB 6669, at p. 7 (Apr. 5, 2023) with OLR Invoice Evaluation sHB 6669 (File 453, as amended by Home “A”), at p. 5 (June 7, 2023).

[vi] See Connecticut Public Act No. 23-171 Sec. 3. (2023); See Connecticut Public Act No. 23-171 Sec. 4(f). (2023).

[vii] ORS 731.244, Or Legal guidelines 2021, ch 593(2021).

[viii] Id.

[ix] Municipal Code of Chicago Sec. 4-5-010.

[x] Medication and Medication – Diabetes – Information and Recordation. 2017 Nevada Legal guidelines Ch. 592 (S.B. 539).

[xi] Nev. Rev. Stat. Ann. § 439B.660.

[xii] SafeRx Modification Act of 2008.


Leave a Reply

Your email address will not be published. Required fields are marked *